The study is a prospective, controlled, randomized two-arm longitudinal crossover trial, performed in a single-centre. Hence, the investigators designed a clinical study aimed to investigate the effects of a daily intake of soffritto in overweight or obese class-1 individuals without other cardiovascular risk. After a run-in period of two-week, participants were randomly separated in two different intervention sequences (two-arms) of six-weeks in which volunteers were administered with a soffritto (100 g/day) or a control group (without soffritto). After the first six-week period, participants had a wash-out phase of two-week followed by a second six-week period in which groups exchanged their interventions. During the duration of the study, the volunteers were asked to maintain their usual diet, excluding raw or cooked tomatoes, as well as tomato-based products (sauces, ketchup, juices, etc.) other than those administered during the study in the corresponding periods.
Sample size (N= 40) was calculated according results of previous studies on pigs (http://dx.doi.org/10.1016/j.trsl.2014.11.004). The study refers to healthy adult men (n=27) and women (n=13) with ages ranging from 25 to 60 years, non-smokers and with overweight (BMI: 25.0-29.9 kg/m2) or obesity class 1 (BMI: 30-34.9 kg/m2). This study received approval from the Human Ethical Review Committee of Hospital Santa Creu I Sant Pau (Barcelona), with the reference number 12/181 and the date of approval being January 11, 2013. To confirm health status, all subjects underwent a complete physical examination conducted by the study physician. The study lasted 16 weeks that were structured in: * 2 weeks of run-in. * 6 weeks of intervention period. During the intervention period, volunteers were administered with soffritto (100 g/day) or a control group (without soffritto). * 2 weeks of wash-out. * 6 weeks of intervention period. During the intervention period, volunteers exchanged their interventions The volunteers visited the center at days 0, 14, 56, 70 and at the end of the intervention period (day 112). Dietary habits were collected. Compliance was monitored by weekly telephone contact with participants and interviewing them at the end of each intervention period. Blood samples were collected early at the morning after twelve-hour fasting at baseline and at the end of each intervention phase. Blood samples were used for determining all variables of the study. Stool samples were obtained at baseline and after 42 days intervention for the study of platelet aggregation, lipid profile, biochemical measurements, vascular endothelial function and hemogram profile.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
40
The intervention trial was a single-center, prospective, controlled, randomized two-arm longitudinal crossover trial lasting 16 weeks. This duration encompassed a 2-week run-in period, a 6-week intervention period (either in the soffito or control group), a 2-week wash-out period, and another 6-week intervention period (soffritto or control group).
Institut Recerca-Hospital Santa Creu I Sant Pau
Barcelona, Spain
Changes from baseline of platelet aggregation (induced by different agonists: arachidonic acid [1 mM], collagen [2 and 5 µM] and ADP [5 and 20 µM] at day 42
By the light transmission technique LTA. For all agonist results were expressed as the percentage of variation respect to the baseline value (100%).
Time frame: At days 0 and 42
Changes from baseline of glucose levels at day 42
Using routine commercially available assays
Time frame: At days 0 and 42
Changes from baseline of standard serum lipid profile (total cholesterol, high density lipoprotein-cholesterol, low density lipoprotein-cholesterol and triacylglycerols expressed as mg/dL) at day 42
Routine commercially available assays were used for triglycerides, total cholesterol and high density lipoprotein cholesterol. Low density lipoprotein cholesterol was calculated using the Friedewald equation
Time frame: At days 0 and 42
Changes from baseline of vascular endothelial function (RHI, lnRHI, FRHI and AI@75) at day 42
Digital plethysmography using the EndoPAT2000-device. Endothelial function was given as the reactive hyperaemia index (RHI) and the arterial stiffness as the augmentation index (AI) and AI standardized to a pulse of 75/min (AI@75). The natural logarithmically transformed RHI (lnRHI) values was also calculated. The Framingham RHI (FRHI) was calculated as the natural log-transformation of the RHI
Time frame: At days 0 and 42
Changes from baseline of hemogram profile at day 42
Digital plethysmography using the EndoPAT2000-device
Time frame: At days 0 and 42
Changes from baseline of hemodynamic profile at day 42
Blood pressure monitor (Sphygmomanometer)
Time frame: At days 0 and 42
Changes from baseline of hepatic enzymes (ALT, AST and GGT) at day 42
Using routine commercially available assays
Time frame: At days 0 and 42
Changes from baseline of renal markers (creatinine, urea and uric acid) at day 42
Using routine commercially available assays
Time frame: At days 0 and 42
Changes from baseline of BMI at day 42
Dividing the body weight in kilograms by the square of height in meters (kg/m2)
Time frame: At days 0 and 42
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.